Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The New Ghostbuster: Elsevier Reviews Articles On Wyeth Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Elsevier's investigation follows reports that Wyeth hired an outside company to write positive articles about its drugs; publisher also responds to Sen. Grassley letter.

You may also be interested in...



Academic Archive of Pharma Marketing Data On Hold Without Funding

A UCSF group wants its Internet site to be a go-to place for internal documents that reveal the marketing behavior of pharma companies. But it may be awhile before the site can resume posting data unearthed in litigation.

Academic Archive of Pharma Marketing Data On Hold Without Funding

A UCSF group wants its Internet site to be a go-to place for internal documents that reveal the marketing behavior of pharma companies. But it may be awhile before the site can resume posting data unearthed in litigation.

J&J Faces New Round Of Risperdal Suits With Ghostwriting Claims

Johnson & Johnson has been hit with another wave of Risperdal (risperidone) product liability suits. While previous suits have claimed the antipsychotic caused diabetes, the current batch alleges that the drug induced gynecomastia, or breast enlargement, in boys and young men

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel